AGL 35.20 Decreased By ▼ -0.50 (-1.4%)
AIRLINK 123.23 Decreased By ▼ -10.27 (-7.69%)
BOP 5.04 Increased By ▲ 0.07 (1.41%)
CNERGY 3.91 Decreased By ▼ -0.12 (-2.98%)
DCL 8.15 Decreased By ▼ -0.27 (-3.21%)
DFML 44.22 Decreased By ▼ -3.18 (-6.71%)
DGKC 74.35 Decreased By ▼ -0.65 (-0.87%)
FCCL 24.47 Increased By ▲ 0.22 (0.91%)
FFBL 48.20 Increased By ▲ 2.20 (4.78%)
FFL 8.78 Decreased By ▼ -0.15 (-1.68%)
HUBC 145.85 Decreased By ▼ -8.25 (-5.35%)
HUMNL 10.85 Decreased By ▼ -0.15 (-1.36%)
KEL 4.00 Decreased By ▼ -0.06 (-1.48%)
KOSM 8.00 Decreased By ▼ -0.88 (-9.91%)
MLCF 32.80 Increased By ▲ 0.05 (0.15%)
NBP 57.15 Decreased By ▼ -0.65 (-1.12%)
OGDC 145.35 Increased By ▲ 2.55 (1.79%)
PAEL 25.75 Decreased By ▼ -0.26 (-1%)
PIBTL 5.76 Decreased By ▼ -0.16 (-2.7%)
PPL 116.80 Increased By ▲ 2.20 (1.92%)
PRL 24.00 Decreased By ▼ -0.15 (-0.62%)
PTC 11.05 Decreased By ▼ -0.42 (-3.66%)
SEARL 58.41 Increased By ▲ 0.41 (0.71%)
TELE 7.49 Decreased By ▼ -0.22 (-2.85%)
TOMCL 41.10 Decreased By ▼ -0.04 (-0.1%)
TPLP 8.31 Decreased By ▼ -0.36 (-4.15%)
TREET 15.20 Increased By ▲ 0.12 (0.8%)
TRG 55.20 Decreased By ▼ -4.70 (-7.85%)
UNITY 27.85 Decreased By ▼ -0.15 (-0.54%)
WTL 1.34 Decreased By ▼ -0.01 (-0.74%)
BR100 8,528 Increased By 68.1 (0.8%)
BR30 26,868 Decreased By -400.5 (-1.47%)
KSE100 81,459 Increased By 998 (1.24%)
KSE30 25,800 Increased By 331.7 (1.3%)

The Federal Health Ministry, after a gap of 7 years, granted permission to local pharmaceutical companies to make an upward revision in the prices from 7 to 20 percent on 240 locally manufactured drugs. The increase came into affect after persistence appeal by the Pakistan Pharmaceutical Manufacturers Association (PPMA).
An official of the PPMA informed that increase in rates of 240 locally manufactured medicines out of total 47,000 produced in the country was necessary, as their cost of manufacturing had exceeded, prices making it virtually impossible for the related pharmaceutical companies to produce them. As a result, shortage of these medicines caused immense hardship for a large number of patients.
Federal Secretary Health and DG Health also attended the meeting besides other high officials of the health department. Members of the delegation informed the minister about static rates of medicines during the last 7 years despite steep rise in inflation, devaluation of the Pakistani rupee and increase in the input price of the pharmaceutical sector, which forced the industry to face worst ever crises.
Massive increase in raw and packaging material rates, majority of which was imported from abroad for catering to the requirement of indigenous industry was also brought to the notice of the minister.
However, despite presentation of all facts and figures, response of the Federal Minister was unfavourable as he failed to give patient hearing to the problems faced by the pharmaceutical industry in the country. He told them plainly that the government would not hesitate importing medicines from India if the local pharmaceutical industry shuts down their businesses.

Copyright Business Recorder, 2008

Comments

Comments are closed.